Business Combination of Kinarus Therapeutics Holding AG (now renamed to Curatis Holding AG) and Curatis AG completed

Kinarus Therapeutics Holding AG / Key word(s): Acquisition/Corporate Action Business Combination of Kinarus Therapeutics Holding AG (now renamed to Curatis Holding AG) and Curatis AG completed 26-Apr-2024 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR

•  
• The Business Combination of Kinarus Therapeutics Holding AG (now renamed to Curatis Holding AG) with Curatis AG and related transactions were completed on 25 April 2024
• The first trading day of the combined entities, Curatis Group (CURN.SW), is today, 26 April 2024
• A total of CHF4.36m in cash was raised in Q1 2024 in connection with the Business Combination
• Curatis Group, a specialty pharmaceutical and therapeutic drug development company focused on orphan and ultra-orphan indications is an exciting addition to the universe of healthcare companies listed on the SIX Swiss Exchange
• Risk-balanced business model with a mix of specialty medicine distribution and targeted own drug development activities, focusing on compounds with existing safety and efficacy data in indications with high unmet medical need
•  

Liestal, Switzerland, 26 April 2024: Curatis Holding AG ("CURN.SW", "Curatis Holding" or the "Company", formerly Kinarus Therapeutics Holding AG, and together with its wholly-owned subsidiary Curatis AG, "Curatis Group"), a SIX Swiss Exchange listed specialty pharmaceutical and therapeutic speciality medicine distribution and drug development company, today announces that it has successfully completed the business combination with Curatis AG (the "Business Combination"). As of today, the CURN.SW shares of the Company, under the new name Curatis Holding AG and with a relocated domicile to Liestal, Basel-Landschaft, are trading for the first time on the SIX Swiss Exchange.